Literature DB >> 7166899

Experimental central serous chorioretinopathy. III: ultrastructural findings.

H Yoshioka, Y Katsume.   

Abstract

Experimental central serous chorioretinopathy was produced in a cynomolgus monkey. The sites of the outer blood retinal barrier coinciding with the spots of fluorescein leakage as confirmed by fluorescein angiography were examined by light and electron microscopy. Degeneration of a few retinal pigment epithelial cells was found, suggesting that the leakage of fluorescein into the subretinal space resulted from the disruption of the outer blood retinal barrier due to degeneration of the retinal pigment epithelial cells. Loss of the diaphragms or defects of damaged endothelial cells were observed in the inner surface of the choriocapillaris underneath these degenerated pigment epithelial cells. The region of these endothelial cell defects was covered with fibrin-platelet clots, and further, a considerable amount of fibrin existed within the Bruch's membrane. It is, thus, suggested that abnormal hyperpermeability of the choriocapillaris plays an important role in the pathogenetic development of this disease. Moreover, the results obtained in this study demonstrate that regional reparation of degenerated retinal pigment epithelial cells at the sites of fluorescein leakage will be initiated by rapid migration of surrounding normal retinal pigment epithelial cells in this experimental model.

Entities:  

Mesh:

Year:  1982        PMID: 7166899

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  12 in total

1.  Type A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Trans Am Ophthalmol Soc       Date:  1986

2.  Serous retinal detachment resembling central serous chorioretinopathy following organ transplantation.

Authors:  T R Friberg; A W Eller
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1990       Impact factor: 3.117

3.  Central serous chorioretinopathy: an analysis of the clinical morphology using image-processing techniques.

Authors:  T R Friberg; J Campagna
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

4.  Intravitreal bevacizumab for iatrogenic choroidal neovascularization due to laser photocoagulation in central serous chorioretinopathy.

Authors:  Yoko Nomura; Ryo Obata; Yasuo Yanagi
Journal:  Jpn J Ophthalmol       Date:  2012-04-20       Impact factor: 2.447

5.  Bullous retinal detachment and multiple retinal pigment epithelial detachments in patients receiving hemodialysis.

Authors:  J D Gass
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

6.  Diffuse retinal pigment epitheliopathy complicating systemic corticosteroid treatment.

Authors:  B C Polak; G S Baarsma; B Snyers
Journal:  Br J Ophthalmol       Date:  1995-10       Impact factor: 4.638

7.  Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy.

Authors:  Takamasa Kinoshita; Yoshinori Mitamura; Terumi Mori; Kei Akaiwa; Kentaro Semba; Mariko Egawa; Junya Mori; Shozo Sonoda; Taiji Sakamoto
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

Review 8.  Retina and the tubercle Bacillus: Four decades of our journey and current understanding.

Authors:  Pradeep Venkatesh
Journal:  Indian J Ophthalmol       Date:  2017-02       Impact factor: 1.848

9.  Evaluation of parafoveal vascular density using optical coherence tomography angiography in patients with central serous chorioretinopathy.

Authors:  Mehmet Emin Dursun; Seyfettin Erdem; Mine Karahan; Sedat Ava; Leyla Hazar; Birgül Dursun; Uğur Keklikçi
Journal:  Lasers Med Sci       Date:  2021-07-03       Impact factor: 3.161

10.  Swept-source optical coherence tomography angiography alleviates shadowing artifacts caused by subretinal fluid.

Authors:  Michael Reich; Daniel Boehringer; Kai Rothaus; Bertan Cakir; Felicitas Bucher; Moritz Daniel; Stefan J Lang; Wolf A Lagrèze; Hansjuergen Agostini; Clemens Lange
Journal:  Int Ophthalmol       Date:  2020-04-24       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.